Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre

Abstract

Isavuconazole may be an option for antifungal prophylaxis in high-risk immunocompromised adults and has the potential to produce significant inpatient drug cost savings. Further studies are needed to confirm the clinical efficacy and cost-effectiveness of isavuconazole in this role.